Mereo BioPharma Group (MREO) Stock Overview
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MREO Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Mereo BioPharma Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.34 |
| 52 Week High | US$3.05 |
| 52 Week Low | US$0.20 |
| Beta | 0.33 |
| 1 Month Change | -19.18% |
| 3 Month Change | -85.04% |
| 1 Year Change | -86.24% |
| 3 Year Change | -56.52% |
| 5 Year Change | -89.65% |
| Change since IPO | -94.73% |
Recent News & Updates
Recent updates
Here's Why We're Not At All Concerned With Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Situation
Sep 27
We're Not Very Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Rate
May 19Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?
Apr 07Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?
Nov 25Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat
Oct 17Rubric Capital boosts Mereo BioPharma board nominees slate to five
Oct 03Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside
Sep 22Mereo activist investor Rubric asks board again to hold general meeting, nominate directors
Sep 14Mereo BioPharma Group regains compliance with Nasdaq's listing rule
Jul 05Mereo BioPharma: Activist Pressure In A Net-Net Biopharma
Jun 17Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development
Dec 08Shareholder Returns
| MREO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.1% | -3.1% | -1.7% |
| 1Y | -86.2% | 20.2% | 13.8% |
Return vs Industry: MREO underperformed the US Biotechs industry which returned 20.8% over the past year.
Return vs Market: MREO underperformed the US Market which returned 13.1% over the past year.
Price Volatility
| MREO volatility | |
|---|---|
| MREO Average Weekly Movement | 32.4% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MREO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MREO's weekly volatility has increased from 19% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 36 | Denise Scots-Knight | www.mereobiopharma.com |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease.
Mereo BioPharma Group plc Fundamentals Summary
| MREO fundamental statistics | |
|---|---|
| Market cap | US$54.42m |
| Earnings (TTM) | -US$41.88m |
| Revenue (TTM) | US$500.00k |
Is MREO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MREO income statement (TTM) | |
|---|---|
| Revenue | US$500.00k |
| Cost of Revenue | US$133.00k |
| Gross Profit | US$367.00k |
| Other Expenses | US$42.25m |
| Earnings | -US$41.88m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 73.40% |
| Net Profit Margin | -8,375.60% |
| Debt/Equity Ratio | 0% |
How did MREO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/23 15:18 |
| End of Day Share Price | 2026/03/23 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mereo BioPharma Group plc is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Yun Zhong | BTIG |
| Julian Harrison | BTIG |